Towards Application of Bioactive Natural Products Containing Isoprenoids for the Regulation of HMG-CoA Reductase—A Review

Sepideh Pakpour
Department of Biology, University of British Columbia, Kelowna, Canada.
Email: sepideh.pakpour@ubc.ca
Received March 1st, 2013; revised April 2nd, 2013; accepted May 1st, 2013

ABSTRACT

Recognition of the biological properties of numerous “natural products” has fueled the current focus of this field, namely, the search for new drugs, antibiotics, insecticides, and herbicides. Based on their biosynthetic origins, natural products can be divided into three major groups: the isoprenoids, alkaloids, and phenolic compounds. Isoprenoids are structurally the most diverse group of secondary natural metabolites with different roles in the growth, development, and reproduction of a diverse range of prokaryotic and eukaryotic cells. Mevalonate and 2-C-methyl-D-erythritol 4-phosphate (MEP) pathways are known to be responsible for biosynthesis of numerous isoprenoids. HMG-CoA reductase is a rate-determining enzyme in mevalonate pathway, producing intermediates such as farnesyl and geranylgeranyl pyrophosphates, which lead to by-products such as cholesterol. Earlier studies have demonstrated that the inhibition of HMG-CoA reductase is one of the most effective approaches for treating hypercholesterolemia and eventually cardiovascular disease (CVD). Statins are HMG-CoA reductase inhibitors and the most prescribed group of drugs worldwide in treating hypercholesterolemia; however the application of this group of drugs may be expensive and has side effects including rashes and gastrointestinal symptoms. For these reasons, there is an important need to examine the viability of natural products as an alternative to statin treatment. This article is a review of different aforementioned areas with a focus on isoprenoids that can be used for the regulation of HMG-CoA reductase.

Keywords: Isoprenoids; HMG-CoA Reductase; Mevalonate Pathway; Hypercholesterolemia

1. Introduction

Primary metabolites are compounds that have important role in nutrition and essential metabolic pathway inside the plants, while natural (secondary) products do not participate directly in growth and development but have ecological roles between the plants and the environment including: 1) protection against herbivory and microbial infections; 2) attractants for pollinators and seed dispersing animals; and 3) act as allelopathic agent to suppress the growth of plant by a toxic released from a nearby plant of the same or another species [1-3]. Plant natural products are divided into three major groups: 1) isoprenoids, 2) alkaloids, and 3) and phenolic compounds, based on their biosynthetic origins.

This article reviews the isoprenoids groups with an interest on discussing their potential effects for treating hypercholesterolemia and cardiovascular disease (CVD). Namely, in Section 2, the isoprenoids’ general definition, classification and synthesis with a focus on mevalonate pathway, as it is the main pathway for the production of cholesterol, are discussed. In Section 3, after an introduction of cholesterol, its different forms and biosynthetic pathway as well as regulation are presented. For the latter, in Section 4, the focus is on the review of HMG-CoA reductase and its regulation since it is the rate-determining enzyme in the mevalonate pathway. Finally, in Section 5, a summary along with potential future developments is presented for exploring other natural products, including those of essential oils of plants as alternatives towards statin treatments.

2. Isoprenoids

Isoprenoids are a large and highly diverse group of natural products. Nearly 35,000 isoprenoids, with largely varying structures and functions, have been identified in viruses, bacteria, fungi, yeast, plants, and mammals [4,5].
In plants, some isoprenoids are vital and moderately universal primary metabolites that act as growth promoters (e.g. abscisic acid, gibberlines, cytokinins) or are essential in photosynthesis (e.g. carotenoid). Also, a group of plants’ isoprenoids are secondary metabolites, such as antimicrobial compounds (phytoalexines) or plant essential oils and natural rubber [6,7]. Moreover, it has been demonstrated that some biologically active compounds, that are derived from intermediates of the isoprenoid pathway (e.g., sterols, oxysterols, farnesol, geranylgeraniol, diphosphate derivatives of isopentenyl (IPP), geranyl (GPP), farnesyl (FPP), geranylgeranyl (GGPP), and presqualene), have a role on the transcriptional and post transcriptional regulations of specific genes [5,8].

Isoprenoids are classified into different groups according to the number of carbon they contain as follows: 1) hemiterpenes (C5H8); 2) monoterpenes (C10H16); 3) sesquiterpenes (C15H24); 4) diterpenes (C20H32); 5) triterpenes (C30H48); 6) tetraterpenes (C40H64); and finally 7) Polytetrapenes (C58H90). All isoprenoids are originated from the universal C5 precursor isopentenyl diphosphate (IPP) and its allylic isomer dimethylallyl diphosphate (DMAPP), and are synthesized through two different biosynthetic pathways: 1) the classical acetate/mevalonate pathway in the cytosol [2].

2.1. Mevalonate Pathway

Isoprenoids that are crucial for diverse cellular function, ranging from cholesterol synthesis to growth control, are produced by mevalonate pathway [8,9]. Synthesis of each IPP in mevalonate pathway requires three molecules of acetyl-CoA, and this pathway starts with two steps condensation of these molecules of acetyl-CoA using two different enzymes (Thioloase and Hydroxymethyl-glutaril-CoA synthase) to form a 3-Hydroxy-3-methyl-glutaryl-CoA. Subsequently, the HMG-CoA molecule is reduced by HMG-CoA reductase to form a Mevalonic acid. This process continues by two subsequent phosphorilations of mevalonic acid using Mevalonate kinase and Phosphomevalonate kinase. Finally, phosphorylation/decarboxylation occurs using mevalonate diphosphate decarboxylase to yield an IPP, followed by an IPP isomerase that keeps the balance between IPP and its allelic isomer, DMAPP. In plants, Mevalonate pathway has more branch pathways than in most other organisms in order to produce a various number of isopronoid products [7].

All enzymes involved in this pathway are the site of drug’s action [15], and the evidence suggests that HMG-CoA reductase is the rate-determining enzyme in mevalonate pathway which catalyzes the conversion of hydroxymethylglutaryl-coenzymeA into mevalonate [16].

3. Cholesterol

Cholesterol (C27) is the major sterol in mammals and a byproduct of mevalonate pathway [17] where 19 enzymes are involved. All these enzymes including HMG-CoA reductase exist in the steroidogenic cells [18]. Cholesterol biosynthesis is divided into two sections: 1) squalene portion where cholesterol biosynthesis starts by the head-to-head condensation of two molecules of FPP to produce presqualene diphosphate, then followed by an NADPH reduction step to produce squalene (C30); and 2) post-squalene portion where the squalene is epoxidized to form oxidosqualene, followed by a cyclization to produce lanosterol. Finally, lanosterol is reformed to produce cholesterol by loosening three methyl groups (C4, C14), and reducing the side-chain double bond (Figure 2) [4, 18,19].

Cholesterol has numerous crucial functions in human body. It is a key compound in cell membranes which can control the membrane over a range of physiological temperatures. Vitamin D is one of the cholesterol derivatives, and also, the human body uses the cholesterol as a precursor for the synthesis of bile acids, which are important for the digestion of dietary fats and fat-soluble vitamins. Finally, another important function of cholesterol is to serve as a substrate for the synthesis of all steroidal hormones including sex hormones, glucocorticoids and mineralocorticoids [13,20]. As a result, an obstruction in cholesterol biosynthesis may lead to multiple congenital anomalies and mental retardation [18].
Two forms of cholesterol are found in cells and plasma: free cholesterol which mainly spread in the plasma membrane, and to a lesser level in intracellular organelle; the second principal form of cholesterol is cholesterol esters, where cholesterol is esterified to long chain polyunsaturated fatty acids and to a lesser level of sulfate.

Figure 1. Schematic representation of isoprenoid biosynthetic pathways and products in different stages [14].
Towards Application of Bioactive Natural Products Containing Isoprenoids for the Regulation of HMG-CoA Reductase—A Review

Figure 2. Overview of the cholesterol biosynthetic pathway. (A) Synthesis of lanosterol, (B) Synthesis of FF-MAS from lanosterol, (C) Conversion of MAS sterols to cholesterol [18].

This form of cholesterol is the main depots of surplus cellular sterol [18]. Cholesterol is insoluble in water and circulated by four different lipoproteins including chylomicron (CM), very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in the blood [21]. Cholesterol ester is 60% - 80% of total cholesterol content of the aforementioned lipoproteins [18]. The dietary cholesterol is absorbed through following steps and is then carried by chylomicron (CM) to adipose tissue and skeletal muscles: 1) first, cholesterol are transported from lumen to the intestine absorptive cells (enterocytes) via NPC1L1; 2) then, cholesterol is converted to cholesterol ester (CE) by using intestinal acyl coenzyme A: cholesterol acyltransferase 2 (ACAT2); 3) the latter product is packed into chylomicrons (CM) by using microsomal triacylglycerols (MTP); and 4) finally it is transferred into blood through the lymphatic system. The unabsorbed cholesterol is returned to the lumen of the intestine by employing ATP binding cassette transporters (ABCG5 ABCG8) [21-23]. LDL is produced in plasma and is the major cholesterol carrier in the blood which provides cholesterol to those tissues that need it. In contrast, HDL eliminates unwanted cholesterol from peripheral tissues back to the liver and have an important role in keeping cholesterol homeostasis in the plasma [13].

Heart disease is the second main cause of death in the world; 6 million people have died of cardiovascular dis-
ease (CVD) in 2008 according to the World Health Organization (WHO) estimation, which is 10.8% of all death worldwide in the same year (http://www.who.int/mediacentre/factsheets/fs310/en/index.html). Also, heart disease is one of the main leading causes of death for Canadians; being responsible for 22% of the 235,217 deaths in Canada in 2007 (http://www.statcan.gc.ca/dailyquotidien/101130/dq101130b-eng.html).

Aging, body weight, blood pressure, smoking and drinking are the main factors which can raise the risk of CVD [24]. Also, studies demonstrated that there is an association between plasma cholesterol concentration and coronary heart disease where the over-accumulation of cholesterol within the body increases the risk of the cardiovascular disease [20].

### 3.1. Regulation of Cholesterol Biosynthesis

Cells gain cholesterol via two different mechanisms: 1) synthesis of endogenous cholesterol from acetyl coenzyme A (CoA) via mevalonate pathway; and 2) the cellular uptake of circulating plasma low-density lipoprotein (LDL) which enters the cell by receptor-mediated endocytosis (exogenously) [25,26]. These internal and external sources are balanced through feedback regulation of HMG-CoA synthase, HMG-CoA reductase as well as LDL receptors, in order to avoid sterol over-accumulation. In the presence of LDL, activities of aforementioned enzymes are 90% lower and mevalonate pathway is shut. In the presence of LDL, activities of aforementioned enzymes are 90% lower and mevalonate pathway is shut.

In the absence of LDL, HMG-CoA synthase and HMG-CoA reductase are highly active to produce non-sterol compounds. In the absence of sterol, the mevalonate pathway shunts into the biosynthesis of non-sterol compounds because the enzymes of non-sterol pathways have higher affinities than those of the sterol pathway [5,8].

It has been illustrated that the higher fruit and vegetable intake results in the lower total cholesterol and low-density lipoprotein cholesterol (LDL-C); however it does not have any effect on the serum total cholesterol (TC) or HDL-C concentration [27,28]. In contrast, other studies illustrated that the consumption of functional foods containing high level of phytosterols resulted in the inhibition of intestinal NPC1L1, subsequently reducing the cholesterol absorption, and finally decreasing serum total cholesterol (TC) and low density lipoprotein (LDL) concentration [29,30].

Generally, cholesterol-lowering agents can be categorized into five major types: acyltransferase (ACAT) inhibitors, LDL receptor activators, acyl-CoA: cholesterol acyltransferase bile acid absorption inhibitors, CETP (a plasma glycoprotein, which facilitates the transmission of CE from HDL to LDL) inhibitors, and HMG-CoA reductase inhibitors [13].

It has been shown that the tripenic acid [3], soya bean [31], naringenin as a citrus bioflavonoid [32], and conjugated linoleic acid [31] are effective in reducing ACAT activity and decreasing the plasma cholesterol levels. On the other hand, it has been investigated that the resveratrol and quercerin (wine polyphenols) [33] and tea cathin [34] are attributed to the up-regulation of LDL receptor activity and subsequently reducing plasma cholesterol level. B-glucan, the active ingredient in oats [35] and calcium supplementation [25] can reduce the reabsorption of bile acids, increasing their excretion into the feces, and thus decreasing the liver and plasma cholesterol. Apple polyphenols [31], garlic [36], and supplementation of red pepper [37] can decrease CETP activity which results in the enhancing the HDL cholesterol concentration. In addition, up regulation of cytochrome P450 (CYP7A1) activators leads to the reduction of hepatic cholesterol. CYP7A1 is the rate limiting enzyme in the conversion of cholesterol to bile acids in the liver [20]. Studies illustrated that buckwheat [6], curcumin (the main ingredient of turmeric) [38], and grape seed polyphenols [39] can reduce plasma cholesterol level by up-regulating the gene of CYP7A1 and increasing bile acid excretion. Despite the positive effects of the above agents, the inhibition of HMG-CoA reductase is known to be the most effective approach to reduce serum cholesterol level [13,40].

### 4. HMG-CoA Reductase

Hydroxymethylglutaryl-coenzymeA reductase (HMG-CoA reductase) catalyzes the conversion of hydroxymethylglutaryl-coenzymeA (HMG-CoA) into mevalonate, the rate-determining step in cholesterol biosynthesis [16,17]. Generally, this enzyme has a short half-life, about 3 hours, and higher cholesterol level decreases even its half-life [18]. Two major classes of HMG-CoA reductase are known: the class I enzyme which is present in eukaryotes and some prokaryotes, and located in the endoplasmic reticulum, such as HMGRh in humans; and the class II enzyme which is found in the majority of the archaeabacteria and certain eubacteria such as HMG Rp in soil bacterium Pseudomonas mevalonii. This group of enzyme is located in cytoplasm [41,42]. The human HMG-CoA reductase gene is located on chromosome 5 and its length is over 24.8 kb [43]. On the other hand, plants contain different HMG-CoA reductase isofoms that seems to be important in directing the flux of pathway intermediates into specific isoprenoid compounds [44]. Plant HMG-CoA reductase has been localized mainly at the endoplasmic reticulum membrane, but HMG-CoA
reductase activity has been reported at other sub-cellular regions including plastids, and mitochondria [7,45]. HMG-CoA reductase is composed of four regions: the N-terminal region, the conserved membrane domain, the linker region, and the catalytic (or cytosolic) domain. Comparing the primary sequences of genes encoding plant HMG-CoA reductases to those of other eukaryotes shows that the membrane and catalytic domain are highly conserved, whereas the N-terminal and the linker regions are highly divergent [7,45]. The main difference in protein structure of HMG-CoA reductases in plants and animals is in the membrane domains which consist of two spans in the membrane domain in plants compared to eight spanning sites in animals (Figure 3) [12,44].

Multigene families are encoding HMG-CoA reductase in plants, two genes in arabidopsis (Arabidopsis thaliana) [45], four genes in tomato [46], and at least 3 genes in potato [47], whereas this enzyme is encoded by a single gene in mammals [48]. Two different HMG-CoA reductase genes (HMG1 and HMG2) in arabidopsis (Arabidopsis thaliana) encode three HMG-CoA reductases isoforms (HMGR1S, HMGR1L, and HMGR2) [44]. It has been demonstrated that the HMG1 is highly expressed in all tissues, whereas the expression of HMG2 gene is restricted to young seedlings, roots and inflorescences [45].

4.1. HMG-CoA Reductase Regulation

HMG-CoA Reductase is regulated by four different mechanisms, including feedback inhibition, control of gene expression, rate of enzyme degradation and phosphorylation-dephosphorylation [49,50]. HMG CoA is a water soluble product which other metabolic pathways can break down when HMG-CoA reductase is inhibited. For this reason, there is no accumulation of potentially toxic precursors, and this phenomenon makes the HMG-CoA reductase an attractive candidate of cholesterol-lowering drugs for reducing low density lipoproteins (LDL-C) and eventually reducing CVD [17].

In plants, developmental signals can control the activity of the HMG-CoA reductase enzyme. HMG-CoA reductase has higher activity in the early stages of plant development and in the rapidly growing parts of plants, such as apical buds and roots. In contrast, the least activity of this enzyme is in mature tissues [51-53]. Also, HMG-CoA reductase activity in plants is regulated by different environmental signals. For example, light can control the HMG-CoA reductase activity at the level of mRNA [54-56]. Also, pathogen-derived elicitor compounds can increases the level of the HMG-CoA reductase activity of those plants that synthesize isoprenoid-phytoalexins as part of their defense. For instance, although, the level of HMG-CoA reductase activity in sweet potato root is very low, its activity is increased rapidly after infection by a fungal pathogen [57,58].

The regulatory role of sterols (cholesterol and/or oxysterols) has been demonstrated as they act as inhibitors of HMG-CoA reductase [8,59,60]. There are sterol regulatory elements (SRE-1) in the 5' flanking regions of the genes encoding for HMG-CoA synthase, HMG-CoA reductase and the LDL receptor. In the LDL receptor gene as well as HMG-CoA synthase, the SRE-1 is a conditional positive element that increases transcription in the absence of sterols but they do not affect the basal level of transcription when they are present. In contrast, it is suggested that the single SRE-1 in the promoter of HMG-CoA reductase repress when sterols are present. Recognition of SRE-1 in the proximal promoter of the aforementioned genes eventually leads to the purification and cloning of a family of transcription factors, termed SRE-binding proteins (SREBPs), which bind to the SRE-1 [5]. Two different SREBP genes (SREBP-1 and SREBP-2) coding for three proteins (SREBP-1a, SREBP-1c, and SREBP-2). SREBP-1a and SREBP-1c are formed from one gene using two promoters and different first exons. The aforementioned proteins are different in length and strength of their activation domains. When the cellular sterol levels decrease, mature SREBP (68 kDa) are released from endoplasmic reticulum by using three additional proteins, the Site-1 and Site-2 proteases and SCAP (SREBP cleavage-activating protein) [5]. In addition, it has been demonstrated that insulin can up-regulate the HMG-CoA reductase while glucagon down regulates it [18]. Moreover, protein kinase catalyzes the inactivation of HMG-CoA reductase by phosphorylation. Because
HMG-CoA reductase is most active in its unmodified form, phosphorylation decreases its activity [7].

4.2. Inhibition of HMG-CoA Reductase

It has been demonstrated that the inhibition of HMG-CoA reductase leads to the activation of transcription factor (SREBP) that promotes expression of the LDL receptor gene, subsequently raising the production of LDL receptors, and thus decreasing the LDL-C level in systemic circulation [61].

Red yeast rice is a typical food that can effectively reduce the blood cholesterol level by inhibiting the HMG-CoA reductase in people with hyperlipidemia [62]. It has been demonstrated that cholesteryl could directly inhibit HMG-CoA reductase followed by the reduction of cholesterol synthesis in hepatic cells (HepG2) [61]. Studies demonstrated that some biologically active compounds derived from mevalonate pathway inhibits the synthesis and enhances the degradation of HMG-CoA Reductase [5]. Fungi contains potent reductase inhibitors, including compactin and mevinolin that block mevalonate synthesis by inhibiting the HMG-CoA reductase as well as 200-fold increase in the reductase protein abundance (inactive form because it is blocked by the inhibitor) in few hours. The 200-fold increase could be the result of the eightfold increase in initiation of transcription (effect of sterol agent), fivefold increase in mRNA translation (effect of non-sterol agent) and fivefold decrease in enzyme molecule degradation (effect of both sterol and non-sterol agent) [8].

Seventeen brands of seven major cholesterol-lowering drug classes are known in the world, which are the HMG-CoA reductase inhibitors (Statins, such as compactin, simvastatin, atorvastatin, etc). These are the most prescribed group of drugs spread throughout the world in treating hypercholesterolemia [63]; however application of this group of drugs has side effects including rashes and gastrointestinal symptoms [20]. Statins exist in two of this group of drugs has side effects including rashes and gastrointestinal symptoms [61]. Studies demonstrated that some biologically active compounds derived from mevalonate pathway inhibits the synthesis and enhances the degradation of HMG-CoA Reductase [5]. Fungi contains potent reductase inhibitors, including compactin and mevinolin that block mevalonate synthesis by inhibiting the HMG-CoA reductase as well as 200-fold increase in the reductase protein abundance (inactive form because it is blocked by the inhibitor) in few hours. The 200-fold increase could be the result of the eightfold increase in initiation of transcription (effect of sterol agent), fivefold increase in mRNA translation (effect of non-sterol agent) and fivefold decrease in enzyme molecule degradation (effect of both sterol and non-sterol agent) [8].

Seventeen brands of seven major cholesterol-lowering drug classes are known in the world, which are the HMG-CoA reductase inhibitors (Statins, such as compactin, simvastatin, atorvastatin, etc). These are the most prescribed group of drugs spread throughout the world in treating hypercholesterolemia [63]; however application of this group of drugs has side effects including rashes and gastrointestinal symptoms [20]. Statins exist in two types: Type I statins which are fungal products such as lovastatin (Mevacor®), simvastatin (Zocor®); and type II which are completely synthetic such as atorvastatin (Lipitor®), fluvastatin (Lescol®) [40].

Isoprenoid derived from plant isoprenoid pathways could suppress HMG-CoA reductase activity by modulating mRNA translation and the proteotoxic degradation. In addition, it has been proposed that aforementioned post-transcriptional procedures are activated directly by acyclic terpenoids and indirectly by cyclic terpenoids [50]. HMG-CoA reductase in vivo in the rat can be inhibited up to 70% by the cyclic monoterpenes as cineole and menthol [64]. Corell et al. (1994) illustrated that farnesol as non-sterol derivatives of mevalonate pathway accelerates the degradation of reductase in animal cells [1], and Elson et al. (1999) suggested it as a key player in the post-translational control of reductase [50]. In contrast, farnesol treatment in tobacco bright yellow-2 Cells (TBY-2) increases the microsomal HMG-CoA reductase activity; however, its effect is concentration dependent [65]. Also, it has been reported that Plantago asiatica essential oils can suppress the expression of HMG-CoA reductase in vitro and in vivo [66]. In addition, tocotrienols, a group of Vitamin E stereoisomers containing farnesylisoprenoid tail, are a group of HMG-CoA reductase inhibitors that are abundant in rice bran and barely [67].

5. Concluding Remarks: Current State and Potential Future Development

The knowledge emerging from the earlier studies reviewed above enables the characterization of some plant biologically active compounds which can inhibit the synthesis and enhance the degradation of HMG-CoA reductase. Cardiovascular disease (CVD) is the main cause of death in industrial countries. Statins are known to be the main treatments for CVD [63]; however the application of this group of drugs, next to their high cost [68], has shown side effects including rashes and gastrointestinal symptoms [69]. For these reasons, there is a necessity to examine the viability of other biologically active natural products as an alternative to statin treatment. In the same relation, an investigation to the essential oils (EOs) may be worthwhile as they are natural products which generally are obtained from flowers, leaves or other parts of plant, and composed of complex mixture of isoprenoids, polyketides and very few alkaloids. They have versatile and varying applications worldwide including folk medicine, Chinese medicine, alternative medicine, aromatherapy, as well as in the cosmetics and perfumes industries, and in food flavoring and cleaning products [70-73]. It is believed that the investigation of different plants essential oils can eventually lead to a discovery of new means for the treatment of hypercholesterolemia and cardiovascular disease (CVD) using natural products.

6. Acknowledgements

Thanks are due to Dr. Soheil S. Mahmoud, the University of British Columbia Okanagan, for his feedback and useful discussions. Financial support from Fonds de Recherche du Québec Nature et Technologies (FQRNT) is greatly acknowledged.

REFERENCES

[1] C. C. Correll, L. Ng and P. A. Edwards, “Identification of Farnesol as the Nonsterol Derivative of Mevalonic Acid Required for the Accelerated Degradation of 3-Hydroxy-3-

Copyright © 2013 SciRes.


Copyright © 2013 SciRes. *AJP*
Towards Application of Bioactive Natural Products Containing Isoprenoids for the Regulation of HMG-CoA Reductase—A Review


Copyright © 2013 SciRes.


